Stock PEPG PEPGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PepGen Inc.

Equities

PEPG

US7133171055

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
14.5 USD -0.41% Intraday chart for PepGen Inc. +7.49% +113.24%
May. 15 PepGen Q1 Loss Narrows MT
May. 14 PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GL
PepGen : Corporate Deck – May 2024
PU
PepGen to Participate in Upcoming Investor Conferences
GL
PepGen to Participate in Upcoming Investor Conferences
AQ
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
GL
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
AQ
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
GL
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
AQ
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
GL
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
AQ
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
GL
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
GL
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
GL
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
GL
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
GL
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
GL
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
GL
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
AQ
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
GL
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PEPG Stock
  4. News PepGen Inc.
  5. Press Releases